| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $62.3M | 0.09% | 686.37K | −45% | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $5.4M | 0.02% | 59.77K | −49% | Q2 2026 |
| Soros Fund Management · George Soros | $4.1M | 0.05% | 44.75K | — | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Richard Dean Dr McCormick GA06 | 5 | 1 | +$32.0K | Sold Jul 30, 26 |
| Mike Kelly PA16 | 1 | −$8.0K | Sold Jul 17, 26 | |
| Richard W. Allen GA12 | 2 | −$65.0K | Sold Jul 14, 26 | |
| Rick Larsen WA02 | 1 | 1 | +$0 | Sold Jul 8, 26 |
| Gilbert Cisneros CA31 | 2 | 3 | −$8.0K | Bought Jun 16, 26 |
| Josh Gottheimer NJ05 | 3 | 3 | +$0 | Trimmed May 27, 26 |
| Julie Johnson TX32 | 4 | −$32.0K | Sold May 12, 26 | |
| Alan Armstrong Sen. OK | 1 | −$32.5K | Sold Mar 27, 26 | |
| Laura Friedman CA30 | +$0 | — Mar 24, 26 | ||
| Thomas H. Kean Jr NJ07 | 3 | +$24.0K | Bought Jan 29, 26 | |
| Julia Letlow LA05 | 1 | 1 | +$0 | Sold Dec 8, 25 |
| Byron Donalds FL19 | 2 | 2 | +$0 | Sold Dec 4, 25 |
| Lisa McClain MI09 | 1 | 1 | +$0 | Sold Jul 10, 25 |
| Jefferson Shreve IN06 | 1 | −$75.0K | Sold May 12, 25 | |
| Bruce Westerman AR04 | 1 | 1 | +$0 | Sold Apr 21, 25 |
| Shelley Moore Capito Sen. WV | 1 | −$8.0K | Trimmed Feb 24, 25 | |
| Jared Moskowitz FL23 | 3 | −$24.0K | Sold Jan 15, 25 | |
| Markwayne Mullin Sen. OK | 1 | −$8.0K | Sold Jan 8, 25 | |
| Emily Randall WA06 | 1 | −$8.0K | Sold Jan 6, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Jul 30, 26 | Richard Dean Dr McCormick GA06 | Self | Sell | $1,001 - $15,000 | Aug 14, 26 (15d) | |
| Jul 17, 26 | Mike Kelly PA16 | Spouse | Sell | $1,001 - $15,000 | Aug 12, 26 (26d) | |
| Jul 14, 26 | Richard W. Allen GA12 | Spouse | Sell | $15,001 - $50,000 | Aug 18, 26 (35d) | |
| Jul 8, 26 | Rick Larsen WA02 | Self | Sell | $1,001 - $15,000 | Jul 12, 26 (4d) | |
| Jun 16, 26 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Jul 2, 26 (16d) | |
| Jun 12, 26 | Richard Dean Dr McCormick GA06 | Self | Buy | $1,001 - $15,000 | Jul 9, 26 (27d) | |
| Jun 12, 26 | Richard Dean Dr McCormick GA06 | Self | Buy | $1,001 - $15,000 | Jul 9, 26 (27d) | |
| May 27, 26 | Josh Gottheimer NJ05 | Joint | Sell (part) | $1,001 - $15,000 | Jun 3, 26 (7d) | |
| May 15, 26 | Gilbert Cisneros CA31 | Self | Sell | $1,001 - $15,000 | Jun 8, 26 (24d) | |
| May 12, 26 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Jun 12, 26 (31d) | |
| Apr 16, 26 | Richard W. Allen GA12 | Spouse | Sell | $15,001 - $50,000 | Jun 5, 26 (50d) | |
| Mar 27, 26 | Alan Armstrong Sen. OK | Self | Sell | $15,001 - $50,000 | Jul 21, 26 (116d) | Report |
| Mar 24, 26 | Laura Friedman CA30 | Self | Exchange | $1,001 - $15,000 | Apr 17, 26 (24d) | |
| Mar 19, 26 | Richard Dean Dr McCormick GA06 | Self | Buy | $1,001 - $15,000 | Apr 7, 26 (19d) | |
| Feb 10, 26 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Mar 9, 26 (27d) | |
| Jan 29, 26 | Thomas H. Kean Jr NJ07 | Self | Buy | $1,001 - $15,000 | Feb 19, 26 (21d) | |
| Dec 19, 25 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Jan 12, 26 (24d) | |
| Dec 18, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Jan 15, 26 (28d) | |
| Dec 8, 25 | Julia Letlow LA05 | Self | Sell | $1,001 - $15,000 | Jan 13, 26 (36d) | |
| Dec 4, 25 | Byron Donalds FL19 | Self | Sell | $1,001 - $15,000 | Jan 7, 26 (34d) | |
| Dec 4, 25 | Byron Donalds FL19 | Spouse | Sell | $1,001 - $15,000 | Jan 7, 26 (34d) | |
| Nov 18, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Dec 15, 25 (27d) | |
| Nov 13, 25 | Julie Johnson TX32 | Joint | Sell (part) | $1,001 - $15,000 | Dec 11, 25 (28d) | |
| Nov 5, 25 | Richard Dean Dr McCormick GA06 | Self | Buy | $1,001 - $15,000 | Dec 9, 25 (34d) | |
| Oct 6, 25 | Rick Larsen WA02 | Self | Buy | $1,001 - $15,000 | Oct 16, 25 (10d) |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Mccoy John A. JrOfficer | Sale at price 109.54 per share. | 27 | $2.96K |
| Aug 24, 2026 | Ford Robert B.Chief Executive Officer | Conversion of Exercise of derivative security at price 44.40 - 59.94 per share. | 398.8K | $21.55M |
| Aug 24, 2026 | Ford Robert B.Chief Executive Officer | Sale at price 115.57 - 116.19 per share. | 398.8K | $46.20M |
| Aug 10, 2026 | Morrone Louis HOfficer | Sale at price 109.83 per share. | 5.8K | $642.51K |
| May 6, 2026 | Stratton John G.Director | Purchase at price 86.82 per share. | 2K | $173.64K |
| Apr 26, 2026 | Starks Daniel JDirector | Purchase at price 92.65 per share. | 10K | $926.54K |
| Apr 23, 2026 | Kumbier Michelle ADirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Babineaux Claire FontenotDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | O Grady Michael GDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Blount Sally EDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Roman Michael FDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Gonzalez Patricia PaolaDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Ahuja Nita M.D.Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Mcdew Darren WDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Mckinstry NancyDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Conroy Kevin TDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Stratton John G.Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 23, 2026 | Starks Daniel JDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 22, 2026 | Boudreau Philip PChief Financial Officer | Purchase at price 91.50 per share. | 2.2K | $201.30K |
| Mar 22, 2026 | Orville Jacob AOfficer | Stock Award(Grant) at price 0.00 per share. | 13.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.8 | 6.5 | -11.8 | -11.6 | -5.7 | 6.0 | 16.5 | 4.4 | -10.4 | 3.0 | −18.7% | ||
| 2025 | 13.1 | 7.9 | -3.9 | -1.4 | 2.2 | 1.8 | -7.2 | 5.1 | 1.0 | -7.7 | 4.3 | -2.8 | +10.8% |
| 2024 | 2.8 | 4.9 | -4.2 | -6.8 | -3.6 | 1.7 | 2.0 | 6.9 | 0.7 | -0.6 | 4.8 | -4.8 | +2.8% |
| 2023 | 0.7 | -8.0 | -0.5 | 9.1 | -7.7 | 6.9 | 2.1 | -7.6 | -5.9 | -2.4 | 10.3 | 5.5 | +0.3% |
| 2022 | -9.4 | -5.4 | -1.9 | -4.1 | 3.5 | -7.5 | 0.2 | -5.7 | -5.7 | 2.3 | 8.7 | 2.1 | −22.0% |
| 2021 | 12.9 | -3.1 | 0.1 | 0.2 | -2.9 | -0.6 | 4.4 | 4.5 | -6.5 | 9.1 | -2.4 | 11.9 | +28.5% |
| 2020 | 0.3 | -11.6 | 2.4 | 16.7 | 3.1 | -3.7 | 10.1 | 8.8 | -0.6 | -3.4 | 3.0 | 1.2 | +26.1% |
| 2019 | 0.9 | 6.4 | 3.0 | -0.5 | -4.3 | 10.5 | 3.6 | -2.0 | -1.9 | -0.1 | 2.2 | 1.7 | +20.1% |
| 2018 | 8.9 | -2.9 | -0.7 | -3.0 | 5.8 | -0.9 | 7.5 | 2.0 | 9.8 | -6.0 | 7.4 | -2.3 | +26.7% |
| 2017 | 8.7 | 7.9 | -1.5 | -1.7 | 4.6 | 6.5 | 1.2 | 3.6 | 4.8 | 1.6 | 3.9 | 1.2 | +48.6% |
| 2016 | -15.7 | 2.4 | 8.0 | -7.0 | 1.9 | -0.8 | 13.8 | -6.1 | 0.6 | -7.2 | -3.0 | 0.9 | −14.5% |
| 2015 | -0.6 | 5.8 | -2.2 | 0.2 | 4.7 | 1.0 | 3.3 | -10.7 | -11.2 | 11.4 | 0.3 | -0.0 | −0.2% |
| 2014 | -4.4 | 8.5 | -3.2 | 0.6 | 3.3 | 2.2 | 3.0 | 0.3 | -1.5 | 4.8 | 2.1 | 1.1 | +17.5% |
| 2013 | 7.8 | -0.3 | 4.5 | 4.5 | -0.7 | -4.9 | 5.0 | -9.0 | -0.4 | 10.1 | 4.5 | 0.4 | +22.0% |
| 2012 | -3.7 | 4.5 | 8.3 | 1.3 | -0.4 | 4.3 | 2.9 | -1.2 | 4.6 | -4.5 | -0.8 | 0.8 | +16.5% |
| 2011 | -5.7 | 6.5 | 2.0 | 6.1 | 0.4 | 0.7 | -2.5 | 2.3 | -2.6 | 5.3 | 1.3 | 3.1 | +17.4% |
| 2010 | -1.9 | 2.5 | -2.9 | -2.9 | -7.0 | -1.6 | 4.9 | 0.5 | 5.9 | -1.8 | -9.4 | 3.0 | −11.3% |
| 2009 | 3.9 | -14.6 | 0.8 | -12.3 | 7.7 | 4.4 | -4.4 | 0.5 | 9.4 | 2.2 | 7.8 | -0.9 | +1.2% |
| 2008 | 0.1 | -4.7 | 3.0 | -4.4 | 6.8 | -6.0 | 6.4 | 1.9 | 0.3 | -4.2 | -5.0 | 1.9 | −5.0% |
| 2007 | 8.8 | 3.1 | 2.2 | 1.5 | -0.5 | -5.0 | -5.3 | 2.4 | 3.3 | 1.9 | 5.3 | -2.4 | +15.3% |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Buy / hold / sell counts